Iterum therapeutics plc (ITRM)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18
Cash flows from operating activities:
Net loss

-16,100

-23,641

-31,271

-27,638

-20,580

-24,257

-24,906

-15,747

-12,146

Adjustments to reconcile net loss to cash used in operating activities:
Depreciation

39

39

39

39

35

37

35

33

31

Share-based compensation expense

597

499

561

573

540

412

474

255

149

Gain on short-term investments

-

0

25

12

88

-

-

-

-

Non-cash gain on short-term investments

-

-

-

-

9

-37

253

39

23

Interest on short-term investments

-

-39

-30

63

11

-

-

-

-

Amortization of debt discount and deferred financing costs

1,614

119

73

72

98

-

-

-

-

Private placement transaction costs included in financing activities

2,130

-

-

-

-

-

-

-

-

Adjustments to fair value of derivatives

1,679

-

-

-

-

-

-

-

-

Other

-378

-727

33

161

-219

-

-

-

-

Changes in operating assets and liabilities:
Prepaid expenses and other current assets

-590

-713

-1,247

491

-1,002

3,778

-1,728

770

793

Other assets

-

-

-

-

-

867

341

1,013

52

Accounts payable

-9,185

959

4,369

3,983

2,135

1,298

-5,463

4,592

422

Accrued expenses

-6,214

-2,179

1,107

5,261

1,662

1,723

1,255

-598

692

Income taxes

121

130

-54

-87

134

138

-78

-22

82

Other liabilities

-334

-

-

-

-190

127

50

67

-2

Net cash used in operating activities

-27,391

-20,016

-25,409

-18,407

-15,053

-23,825

-27,495

-12,930

-11,640

Cash flows from investing activities:
Purchases of property and equipment

-

2

0

12

10

21

16

32

21

Purchases of short-term investments

-

-

-

-

-

7,758

35,008

47,355

6,372

Proceeds from sale of short-term investments

-

0

25

5,000

35,100

36,525

17,250

18,400

15,750

Net cash provided by investing activities

-

-2

25

4,988

35,090

28,746

-17,774

-28,987

9,357

Cash flows from financing activities:
Repayments of long-term debt

1,552

-

-

-

-

-

-

-

-

Proceeds from private placement, net of transactions costs

47,423

-

-

-

-

-

-

-

-

Proceeds from exercise of share options

-

0

0

11

49

-

-

-

-

Net cash provided by financing activities

45,871

-4,071

3,037

11

49

7

0

88,659

32,176

Effect of exchange rates on cash and cash equivalents

-24

7

-11

16

-34

-

-

-

-

Net increase in cash, cash equivalents and restricted cash

18,456

-24,082

-22,358

-13,392

20,052

4,953

-45,303

46,643

29,893

Supplemental Disclosure of Cash Flow Information:
Interest paid

294

332

357

360

350

-

-

-

-

Exchangeable Notes
Amortization of debt discount and deferred financing costs

1,589

-

-

-

-

-

-

-

-

Interest on exchangeable notes - non-cash

652

-

-

-

-

-

-

-

-

Series B Convertible Preferred Shares
Proceeds from issuance of convertible preferred shares

-

-

-

-

-

2

0

-3

32,176